BSEResult2d ago · 3 Nov 2026, 02:06 pm
We hereby submit Unaudited Financial Results for the second quarter and half year ended September 30, 2026.
Yatharth Hospital & Trauma Care Services Ltd · 543950
✦ AI SummaryResults
Yatharth Hospital & Trauma Care Services Ltd has submitted unaudited financial results for the second quarter and half year ended September 30, 2026, with the Board of Directors approving the results at its meeting held on November 03, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Yatharth Hospital & Trauma Care Services Ltd - 543950 - Results - Unaudited Financial Results For The Q2FY27
Attachments (1)
📄pdf
Download →
c80fe6a1-5caf-436e-bd46-4d5005fbbdc7.pdf
View document text
Yatharth Hospital & Trauma Care
CIN No.: L85110DL2008PLCI174706
Services Limited
YH/SE/65/2026-27
November 03, 2026
The Listing Department Dept. of Listing Operations
National Stock Exchange of India Limited BSE Limited,
Exchange Plaza, 5th Floor, Plot No. C/1 Phiroze Jeejeebhoy Towers,
G Block, Bandra-Kurla Complex, Bandra (E) Dalal Street,
Mumbai - 400 051, India Mumbai -400001, India
Symbol: YATHARTH Scrip Code: 543950
ISIN: INEOJO301016 ISIN: INEOJO301016
Sub: Outcome of Board Meeting - Financial Results.
Dear Sir/Madam,
Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we
hereby inform you that the Board of Directors of Yatharth Hospital & Trauma Care Services
Limited (“Company”), at its meeting held today, i.e., November 03, 2026, has, inter alia,
considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the
second quarter and half year ended September 30, 2026. The copy of the said financial results,
along with the Limited Review Report issued by M/s. M S K A & Associates LLP (formerly known
as M/s. M S K A & Associates), Statutory Auditor of the Company, is enclosed herewith.
The aforesaid information will also be available on the Company’s website at
https: //www.yatharthhospitals.com/investors/financial-section/quaterly-results
The Board Meeting commenced at 01:18 P.M. (IST) and concluded at 01:52 P.M. (IST).
This is for your kind information and records.
Thanking You
Yours Faithfully,
For Yatharth Hospital & Trauma Care Services Limited
Ritesh Mishra
Company Secretary & Compliance Officer
M. No. A51166
Encl.: A/a
Registered Office Our Hospitals
JA-D1LF 0Tow8er, A, Jasola District Centre, New Delhi-| 10025 @ Sector Omega-01, Greater Noida, Uttar Pradesh-201308
Tel: 011-49967892 9 Sector-01, Greater Noida West, Uttar Pradesh-201306
" 9 Sector-110, Noida, Uttar Pradesh-201304
Corporate Office 9 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301 9 Sector88, Faridabed,Haryana-121002
Tok: 0120:681 1238 | Emall;cs@yatharibhosplale.com @ 4C Institutional Area, North ExtensMoideol Tno,wn 3, New Delhi- 110009
Webs wwwtyatharthhospials.com @ Plot No.9 & 9A, Sector 208, Faridabad, Haryana- 121001
@ NHI9, Near Gurudwara Guru Ka Taal, SikandArgara,, Uttar Pradesh-282007
MSKA & Associates LLP MU i oraG 1l0o1b a2l1 1P3ar0k 5, Floo 21
(Formerly known as M S K A & Associates) éeu‘rfg'r:ri ;‘{;S‘dm;zve
Chartered Accountants
Independent Auditor’s Review Report on Standalone unaudited financial results of Yatharth
Hospital & Trauma Care Services Limited for the quarter and year to date pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as
amended.
To The Board of Directors of Yatharth Hospital & Trauma Care Services Limited
1. We have reviewed the accompanying statement of standalone unaudited financial results of
Yatharth Hospital & Trauma Care Services Limited (hereinafter referred to as ‘the Company’) for
the quarter ended September, 2026 and the year to-date results for the period from April 01, 2026
to September 30, 2026 (‘the Statement’) attached herewith, being submitted by the Company
pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’)...
2. This Statement, which is the responsibility of the Company’s Management and has been approved
by the Company’s Board of Directors, has been prepared in accordance with the recognition and
measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’,
prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued
thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and
is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement
based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review
Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent
Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim
financial information consists of making inquiries, primarily of persons responsible for financial and
accounting matters, and applying analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with Standards on Auditing specified under
section 143(10) of the Act and consequently does not enable us to obtain assurance that we would
become aware of all significant matters that might be identified in an audit. Accordingly, we do not
express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention
that causes us to believe that the accompanying Statement prepared in accordance with the
recognition and measurement principles laid down in Ind AS 34 and other recognised accounting
principles generally accepted in India has not disclosed the information required to be disclosed in
terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any
material misstatement.
For MS K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187
UV‘W
Sumit Verma
Partner
‘Membership No.: 509426
UDIN: 26509426 WCYTFN7113
Place: Gurugram
Date: November 03, 2026
Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India
Tel: +91 22 6974 0200 | LLPIN: ACT-3789
Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa| Hyderabad | Kochi | Kolkata | Mumbai | Pune www.mska.in
YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED
Registered office : JA 108, DLF Tower A, Jasola District Centre, South Delh, Delhi, India, 110025
Corporate office: Sovereign Capital Gate, FC 12, Sector 164, Noida, Gautam Buddha Nagar, Uttar Pradesh, India, 201301
[Website: www.yatharthhospitals.com
E-mail: cs@yatharthhospitals.com
(CIN: L85110DL2008PLC 174706
Statement of standalone unaudited financial results for the quarter and half year ended September 30, 2026
(Amounts in INR million, unless otherwise stated)
Quarter ended Half year ended Year ended
Sr. [Particulars September 30, | June 30, | September 30, | September 30, | September 30, | March 31, 2026
No. 2026 2026 2025 2026 2025
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | _(Unaudited) (Audited)
T [income
() Revenue from operations 1,949.06 1,763.08 1,383.72 3,712.14 2,690.94 5,918.8¢
(b) Other income 146.45 133.30 50.65 279.75 17.46 22.10
Total income 2,095.51 | 1,896.38 1,434.37 3,991.89 2,808.40 6,150.94
2 |Expenses
Purchase of drugs, consumables and implants 367.73 326.63 27077 696.36 543.29 1,145.98
Changes in inventories of drugs, consumables and mplants (7.54) .59 (10.36) (16.07) 10.38)] 5.58
Employee benefits expense 386.70 347.87 277.96 734.57 513.34 1,143.77
Finance costs 58.03 5313 185 EIERTS 3.4 57.31
Depreciation and amortisation expense 105.62 100.89 63.18 20651 110.05 304.59
Other expenes 743.60 693,54 565.00 1,437.14 1,008.02 2,221.87
Total expenses 1,654.14 | 1,515.53 1,168.40 3,169.67 2,167.74 4,879.10
3 |Profit before tax (1-2) 44137 380.85 265.97 822.22 640.66 1,271.84
4 |Tax expense
- Current tax 99.02 87.34 56.09 186.36 157.74 311.35
- Income tax of earlier years - - - - (7.19)
- Deferred tax (28.26) 11.83 (16.43) 5.29 13.58
Total tax expenses 70.76 99.17 59.56 169.93 163.03 317.74
5 |Net Profit (3-4) 370.61 281.68 206.41 652.29 477.63 954.10
6 |Other comprehensive income .
(i) Items that will nat be reclass:~d to profit or loss 6.83 0.93 L6t 7.76 (023) 3.5
(i) Income tax relating to items that will not be reclas
[Showing first 8,000 characters — download PDF for full document]